Rivastigmine Sandoz-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
scientific-conclusion
medication.label.permit_number
EMA/594840/2024
medication.label.permit_validity
First published: 2025-04-04T14:54:28Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live